GlassScriptPhysician profile
Daniel Mulligan Knowles
NPI 1972169373
$7,298.31
in general payments reported to CMS, 2019-2025
40 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,187 · 2022: $1,672 · 2023: $1,864 · 2024: $1,468 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,365 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,364.69 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $896.61 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $739.71 | 2021-2024 | Lifevest |
| Pfizer INC. | $568.28 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $502.64 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $468.88 | 2021-2025 | |
| Amgen INC. | $377.56 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $366.06 | 2023-2025 | Amplatzer Amulet, Cardiomems, Jot Dx |
| Merck Sharp & Dohme LLC | $358.69 | 2021-2025 | Verquvo, Winrevair |
| Boston Scientific Corporation | $289.94 | 2021-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Esperion Therapeutics, INC. | $262.37 | 2021-2025 | Nexletol |
| Biotronik INC. | $250.40 | 2022-2024 | Biomonitor, Amvia Edge |
| Scpharmaceuticals INC. | $248.26 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $234.21 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $219.28 | 2021-2024 | Farxiga |
| Philips North America LLC | $204.72 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $141.61 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $124.39 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $121.52 | 2022-2025 | Onpattro |
| Novo Nordisk INC | $100.33 | 2021-2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $99.27 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $89.05 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Amarin Pharma, INC. | $78.47 | 2021-2022 | |
| Bridgebio Pharma, INC. | $64.32 | 2025 | Attruby |
| United Therapeutics Corporation | $56.86 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.74 | 2022-2024 | Evkeeza, Praluent |
| Impulse Dynamics (USA) INC. | $42.96 | 2023 | Optimizer |
| Becton, Dickinson and Company | $42.20 | 2025 | Hemosphere |
| Bayer Healthcare Pharmaceuticals INC. | $40.71 | 2025 | |
| Lilly USA, LLC | $40.42 | 2021 | |
| Medicomp INC | $32.52 | 2022 | |
| Optinose US, INC. | $26.48 | 2021 | |
| Nestle Healthcare Nutrition INC. | $26.26 | 2021 | |
| Medtronic, INC. | $23.11 | 2025 | Linq II |
| Xeris Pharmaceuticals, INC. | $20.32 | 2023 | Keveyis |
| Edwards Lifesciences Corporation | $19.98 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lexicon Pharmaceuticals, INC. | $16.49 | 2024 | |
| Glaxosmithkline, LLC. | $15.61 | 2025 | Arexvy, Shingrix |
| Cvrx, INC. | $14.53 | 2024 | Barostim Neo System |
| Astellas Pharma US INC | $14.30 | 2021 | |
| Abbvie INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.